Home › Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital
 

Keywords :   


Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital

2016-04-11 07:30:57| Biotech - Topix.net

's stock had its "buy" rating restated by equities research analysts at Roth Capital in a research report issued to clients and investors on Saturday, MarketBeat reports. Other hedge funds have made changes to their positions in the company.

Tags: rating stock capital roth

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Dine and dash couple hit my pizzeria, says owner
15.05Boeing may face criminal prosecution, US says
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
More »